<< Study explores incidence of eating disorders among type 1 diabetic patients | Today's OpEds: Rove on reconciliation, an imagined plea from Kennedy, vulnerable Hispanics >>
Read in | English | Italiano

Sigma-Aldrich announces global licensing agreement with CSIRO for RAFT agents

Published on March 12, 2010 at 12:13 AM · No Comments

Sigma-Aldrich (Nasdaq: SIAL) announced today that it has entered into a worldwide licensing agreement with Australia's Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell Reversible Addition-Fragmentation chain Transfer (RAFT) agents – organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers.  Under the terms of the agreement, Sigma-Aldrich has the rights to manufacture and sell the RAFT agents worldwide for all research and development applications.  The RAFT agents are the latest addition to Sigma-Aldrich's growing line of polymer science products sold through its Aldrich® Materials Science Initiative.

"Commercial availability of RAFT agents is a critical requirement toward making RAFT polymerization accessible to the wider community of materials researchers," said Dr. Ilya Koltover, market segment manager for Aldrich Materials Science.  "We have successfully scaled up synthesis of RAFT agents and are pleased to offer a selection that is expected to enable researchers to explore a variety of experimental conditions without having to go through the trouble of making the RAFT agents in their own labs.  This effort is another example of the core value of Aldrich Materials Science - we focus on supplying materials so that our customers can focus on results."

RAFT technology is a living radical polymerization process and a powerful method for the synthesis of tailor-made polymers with predetermined molecular weights and highly complex architectures.  Such designer polymers can be used to prepare materials with unique properties controlled by their nanometer scale molecular architecture in industries such as biomedical, specialty chemical and personal care.  The RAFT method is applicable to a wide range of monomers and experimental conditions and its utility is reflected in more than 200 patents related to RAFT technology.  Sigma-Aldrich will manufacture and distribute the critical components of RAFT polymerization, RAFT agents, to enable companies and research organizations to undertake further research into this groundbreaking technology.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading